Skip to main content
. 2018 Jul 12;91(1088):20170653. doi: 10.1259/bjr.20170653

Table 2.

At-rest testing

Area MBF [ml/(g*min)]before RT MBF [ml/(g*min)]2 months after RT MBF [ml/(g*min)]8 months after RT p-value
Global 1.15 ± 0.33 1.14 ± 0.35 1.15 ± 0.25 1 vs 2 p = 0.841
1 vs 3 p = 0.960
LAD 1.20 ± 0.35 1.16 ± 0.36 1.11 ± 0.27 1 vs 2 p = 0.472
1 vs 3 p = 0.197
Cx 1.30 ± 0.42 1.23 ± 0.33 1.27 ± 0.28 1 vs 2 p = 0.230
1 vs 3 p = 0.735
RCA 0.99 ± 0.30 1.08 ± 0.45 1.36 ± 0.94 1 vs 2 p = 0.411
1 vs 3 p = 0.204
Seg 1 1.03 ± 0.28 0.94 ± 0.30 0.93 ± 0.18 1 vs 2 p = 0.058
1 vs 3 p = 0.053
Seg 2 0.81 ± 0.16 0.79 ± 0.21 0.79 ± 0.12 1 vs 2 p = 0.574
1 vs 3 p = 0.728
Seg 3 0.85 ± 0.23 0.84 ± 0.29 0.89 ± 0.27 1 vs 2 p = 0.851
1 vs 3 p = 0.526
Seg 4 1.01 ± 0.30 1.06 ± 0.42 1.80 ± 2.60 1 vs 2 p = 0.578
1 vs 3 p = 0.319
Seg 5 1.15 ± 0.39 1.10 ± 0.36 1.15 ± 0.23 1 vs 2 p = 0.204
1 vs 3 p = 0.995
Seg 6 1.25 ± 0.29 1.17 ± 0.33 1.19 ± 0.31 1 vs 2 p = 0.072
1 vs 3 p = 0.334
Seg 7 1.23 ± 0.30 1.10 ± 0.27 1.09 ± 0.24 1 vs 2 p = 0.009
1 vs 3 p = 0.026
Seg 8 0.88 ± 0.20 0.87 ± 0.24 0.86 ± 0.17 1 vs 2 p = 0.759
1 vs 3 p = 0.752
Seg 9 0.88 ± 0.24 0.89 ± 0.28 0.98 ± 0.28 1 vs 2 p = 0.882
1 vs 3 p = 0.291
Seg 10 1.07 ± 0.37 1.16 ± 0.54 1.91 ± 2.36 1 vs 2 p = 0.451
1 vs 3 p = 0.225
Seg 11 1.27 ± 0.44 1.25 ± 0.40 1.36 ± 0.27 1 vs 2 p = 0.862
1 vs 3 p = 0.385
Seg 12 1.40 ± 0.47 1.27 ± 0.31 1.28 ± 0.31 1 vs 2 p = 0.173
1 vs 3 p = 0.252
Seg 13 1.28 ± 0.39 1.22 ± 0.34 1.13 ± 0.34 1 vs 2 p = 0.170
1 vs 3 p = 0.054
Seg 14 0.99 ± 0.30 1.01 ± 0.35 1.03 ± 0.29 1 vs 2 p = 0.762
1 vs 3 p = 0.679
Seg 15 1.13 ± 0.40 1.42 ± 0.80 2.07 ± 2.33 1 vs 2 p = 0.199
1 vs 3 p = 0.175
Seg 16 1.44 ± 0.51 1.32 ± 0.31 1.41 ± 0.45 1 vs 2 p = 0.226
1 vs 3 p = 0.722
Seg 17 1.53 ± 0.63 1.44 ± 0.51 1.38 ± 0.50 1 vs 2 p = 0.505
1 vs 3 p = 0.181

Cx, left circumflex artery; LAD, left anterior descending artery; MBF, myocardial blood flow; RCA, right coronary artery; RT, radiotherapy.

Significant MBF decreases after RT were only observed in one segment localized in the anterior mid-cavity wall supplied by the LAD. Significant differences are highlighted in bold.